A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Destiny Pharma
Ticker: DEST Exchange: AIM www.destinypharma.com

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Destiny Pharma 27 Nov 2020

Competition for XF-73 moves aside, issue approved

Our previous note discussed Destiny’s acquisition of the Phase 3-ready NTCD M3 product for the...

Read more
Destiny Pharma 10 Nov 2020

A group transformed

While completing the Phase 2b study of their first product, Destiny have announced the planned...

Read more
Destiny Pharma 17 Sep 2020

Plenty of progress in H1

Having navigated the challenge of running a clinical trial during a global pandemic, Destiny has...

Read more
Destiny Pharma 07 Sep 2020

Yet another string to Destiny's bow

Destiny Pharma have always had a microbiome tilt with their most advanced product, topical XF-73,...

Read more
Destiny Pharma 27 Jul 2020

New Model Anti-infectives

Destiny's lead product XF-73 is in the US and European Phase 2b study for a new preventative...

Read more
Destiny Pharma 29 Apr 2020

Differentiated drugs

FY 2019 results featured its ongoing Phase IIb study of its lead drug XF-73 for the prevention of...

Read more
Destiny Pharma 18 Dec 2019

Anti-microbial agents with unique properties

Following the set of largely established US and EU guidelines which recommend the decolonisation of...

Read more
Destiny Pharma 15 Apr 2019

Bucking the Big Pharma trend

Lead asset XF-73 has potential to be first to a $1.2bn core market. We think that its low...

Read more
Destiny Pharma 05 Oct 2018

Extending the clinical pipeline

Their pipeline of novel antimicrobials include eight so far tested of those classed as urgent...

Read more
Destiny Pharma 12 Aug 2018

Clinical progress with XF drug platform

Recently, positive results from a blinded, placebo-controlled Phase I dermal irritancy study of...

Read more
Destiny Pharma 26 Apr 2018

Well-funded and on track for Phase IIb

  Destiny is on target for delivering the clinical plan for its novel antimicrobial candidate XF-73...

Read more
  • 1 of 2 pages

Register for updates

Sign up to get access to our latest content as soon as it’s published

Register For Updates